Surrozen, Inc. (SRZN)
SRZNNASDAQ-CMBiotechnology: Biological Products (No Diagnostic Substances)
$31.61
-0.0800 (-0.25%) today
Closed, Nov 13, 4:00 PM ET
- Market cap
- $602.54m
- P/E
- –
- EPS, last 4 quarters
- $-17.38
- Dividend yield
- –
- Day range
- –
- 52-week range
- $12.12 to $37.83
- Average volume
- –
- Previous close
- $31.69
Analysts
5 coveringBuy5 buy, 0 hold, 0 sell
Targets a year out average $62.50, +97.7% from here
Earnings
next estimate $-1.17Next report
Dec 2025
-438.3%
Mar 2026
-233.1%
Jun 2026
+69.4%
Sep 2026
-259.9%
estimate reported, and the surprise
Financials
| Quarter | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| Revenue | $528.0k | $5.00m | $5.00m | – |
| Gross profit | $528.0k | $5.00m | $5.00m | – |
| Operating income | -$12.64m | -$10.46m | -$10.37m | -$17.64m |
| Net income | -$183.16m | -$127.50m | $50.18m | -$129.72m |
News
8 latest- Surrozen, Inc. Reports Third Quarter 2026 Financial Results and Plans to Expand DUET Study to 150 PatientsFintel · 4 days ago
- Surrozen's SZN-8141 IND Cleared By FDA For Diabetic Macular Edema RTTNews · Oct 2, 2026
- Surrozen Submits IND Application For SZN-8141 In Diabetic Macular Edema RTTNews · Sep 8, 2026
- Surrozen Highlights Wnt Retina Pipeline, SZN-8141 IND Timeline at H.C. WainwrightMarketBeat · Jul 22, 2026
- Surrozen (SRZN) Price Target Increased by 10.11% to 43.52Fintel · May 14, 2026
- TD Cowen Initiates Coverage of Surrozen (SRZN) with Buy RecommendationFintel · Apr 21, 2026
- Avita Medical (RCEL) Soars 14.1%: Is Further Upside Left in the Stock?Zacks · Apr 15, 2026
- Surrozen (SRZN) Surges 5.9%: Is This an Indication of Further Gains?Zacks · Apr 14, 2026
The company
Surrozen is a biotechnology company, pioneering a new class of Wnt-based therapeutics designed to harness the power of Wnt signaling to treat sight-threatening ophthalmic conditions. Built on deep scientific expertise and a proprietary antibody-engineering platform, Surrozen develops multifunctional biologics that selectively activate Wnt signaling in combination with other key disease pathways. Surrozen's approach aims to deliver best-in-class, durable therapies that have the potential to transform patient outcomes in some of the most pressing unmet medical needs in ocular diseases.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ-CM
- Region
- North America
- Website
- surrozen.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.